VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

EBMT 2020 | European regulation of advanced therapies

Aurélie Mahalatchimy • 1 Sep 2020
EBMT 2020
General CAR-T
Clinical Practice Communication Perspectives Policy

Aurélie Mahalatchimy, PhD, Aix-en-Provence, Provence-Alpes-Côte d’Azur, France, discusses European regulation of advanced therapies and medicinal products, highlighting CAR T-cells. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

More from Aurélie Mahalatchimy

5:43
Gene editing: legal and ethical considerations
Aurélie Mahalatchimy • 1 Sep 2020
1:57
European regulation and access to advanced therapies
Aurélie Mahalatchimy • 1 Sep 2020

Related Videos

0:55
Multivalent gamma-delta T-cells: promising agents for the treatment of cancers
Jürgen Kuball • 10 Feb 2023
1:26
Rapid CAR-T manufacturing and challenges in this space
Nina Worel • 9 Feb 2023
1:13
An insight into novel third-generation TLR2 co-stimulatory CAR-T cells
Yasmin Nouri • 9 Feb 2023
3:00
Addressing challenges in using MSCs in cell therapies
Ross Macdonald • 19 Apr 2022
The content of VJRegenMed is intended for healthcare professionals